ReviewJournal of multidisciplinary healthcare2025
A Review of the Impact of Platform Therapies (DMTs) on Associated Clinical Symptoms of Multiple Sclerosis.
Review in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integrative Transcriptomics Uncovers IFN-β Signature and IFITM3 as Putative Molecular Mediator in MS.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persons with multiple sclerosis (pwMS) experience varied symptoms, often influencing clinical decisions. Symptoms including cognitive deficits, pain, fatigue, and depression profoundly impact quality of life (QoL). Disease-modifying therapies (DMTs) primarily focus on reducing relapses and delaying progression; however, their ability to alleviate symptoms is less known. This narrative review consolidates the current evidence of the role of platform DMTs (Glatiramer Acetate (GA), Interferon (IFN), Dimethyl Fumarate (DMF), Teriflunomide (TER)) on the associated symptoms of MS and their efficacy in prevention of relapse, and disease progression. A literature search was conducted using the PubMed database for studies assessing the impact of GA and other platform DMTs on associated symptoms and effectiveness in pwMS. Studies using specific validated scales to assess each of the symptoms in pwMS treated with platform therapies were considered. A total of 132 publications were identified, and of which 13 were found appropriate for inclusion in the review. Effectiveness outcomes included annual relapse/exacerbation rates and lesion size. The impact of platform DMTs was evaluated in 13 studies in patients with MS having associated symptoms such as cognitive deficits (n=4), pain and spasticity (n=3), and fatigue, depression and overall QoL (n=6). Additionally, eight studies assessed the overall effectiveness of GA in the treatment and management of pwMS. Although a limited number of studies compared the impact of platform therapies on MS-related symptoms, treatment with GA demonstrated statistically significant improvements in cognition, pain, spasticity and fatigue, which was also clinically meaningful on minimum detectable change parameters. This review offers insights and proposes a hypothesis for conducting a large-scale study to explore the impact of platform therapies on MS symptoms that affect quality of life. It may also aid clinicians in making evidence-based therapeutic decisions for the effective management of PwMS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.